SlideShare a Scribd company logo
1 of 32
Chapter 5 
Adverse Effects and Drug 
Interactions 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins 
Question 
• All drugs have some type of adverse effect(s). 
– A. True 
– B. False
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins 
Answer 
• A. True 
• Rationale: All drugs produce some type of adverse 
effect; some of the effects are mild, and others can 
be life threatening.
Adverse Effects 
• An adverse effect of drug therapy is a usually undesirable 
effect other than the intended therapeutic effect. 
• It may occur even with normal drug dosing. 
• An adverse effect may result from 
– Too much of a therapeutic effect 
– Other pharmacodynamic effects of the drug 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Drug Interactions 
• A drug interaction occurs when two drugs or a drug and 
another element have an effect on each other. 
• This interaction may 
– Increase or decrease the therapeutic effect of the 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins 
drugs 
– Create a new effect 
– Increase the incidence of an adverse effect
Adverse Effects 
• Every drug can produce adverse effects. 
• Serious adverse effects lead to the withdrawal of a small 
number of drugs from the market every year. 
• It is important for nurses and other health care 
professionals to be alert for adverse effects from drug 
therapy. 
• Serious adverse reactions to a drug, especially a newly 
approved drug, should be reported to a national 
database. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Allergic and Idiosyncratic Response 
• An allergic response is an immune system response. 
• The antigen–antibody response when the drug is taken 
again 
• Symptoms may become more severe each time the drug 
is introduced into the body. 
• The most serious allergic response is called anaphylaxis. 
• Idiosyncratic responses are unusual and in fact may be 
the opposite of what is anticipated. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins 
Question 
• Which of the following is not a symptom of anaphylaxis? 
– A. Bronchospasms 
– B. Vasodilation 
– C. Convulsions 
– D. Pruritus
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins 
Answer 
• D. Pruritus 
• Rationale: Pruritus is itching and is not a sign of 
anaphylaxis but is considered an allergic reaction.
Toxicities 
• Neurotoxicity (central nervous system) 
– Signs and symptoms: drowsiness, auditory and visual 
disturbances, and seizures 
• Hepatotoxicity (liver) 
– Manifestations include hepatitis, jaundice, elevated 
liver enzyme levels, and fatty infiltration of the liver. 
• Nephrotoxicity (kidneys) 
– Signs and symptoms: decreased urinary output, 
elevated blood urea nitrogen, increased serum 
creatinine, altered acid-base balance, and electrolyte 
imbalances 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Toxicities (cont.) 
• Ototoxicity (eighth cranial nerve) 
– Signs and symptoms: tinnitus, hearing loss, light-headedness, 
vertigo, nausea, and vomiting 
• Cardiotoxicity (heart) 
– Signs and symptoms: irregularities in conduction, 
heart failure, and damage to the myocardium 
• Immunotoxicity (immune system) 
– Signs and symptoms: immunosuppression, increased 
incidence of bacterial, viral, and parasitic infections 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Drug Interactions 
• Drug interactions occur when one drug is affected in 
some way by another drug. 
• Drug interactions may be beneficial. 
• Negative effects from drug interactions are those that 
decrease the therapeutic effect. 
• Drug interactions may take place in any phase of 
pharmacokinetics. 
• Drug interactions can also change the pharmacodynamics 
of a drug. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Drug Interactions (cont.) 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Drug Interactions Affecting Absorption 
• Drug absorption is often decreased because of drug 
interactions. 
• If a drug binds with another substance in the GI tract, 
less of the drug is available to be absorbed. 
• This binding of a drug is termed chelation. 
• Drug absorption may also be increased as a result of a 
drug interaction or the presence of food in the GI tract. 
• The exact extent of changes in drug absorption caused by 
drug interactions is often difficult to predict. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Drug Interactions Affecting Distribution 
• Distribution is affected by two types of drug interactions. 
• The first is competitive protein binding. 
• The second is drug alteration of the extracellular pH. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Drug Interactions Affecting Metabolism 
• Probably the most important and common drug 
interaction is one that alters the metabolism of a drug. 
• Drugs that induce a hepatic enzyme increase the amount 
of that enzyme in the liver. 
• If two drugs that affect the cytochrome P-450 system 
must be administered to a patient together, the dose of 
one of the drugs may have to be adjusted. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Drug Interactions Affecting Excretion 
• Drugs can alter renal filtration, renal reabsorption, or 
renal secretion. 
• Glomerular filtration is dependent on blood flow to the 
kidney. 
• Drugs that decrease cardiac output decrease the amount 
of circulating blood that is sent to the kidneys. 
• Renal reabsorption of a drug is dependent on whether a 
drug is ionized. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Drug Interactions Affecting 
Pharmacodynamics 
• Drug interactions may affect the pharmacodynamics of 
one or both drugs administered. 
• The overall effect may be positive or negative. 
• The drug that has the weaker affinity for the receptor will 
not be able to exert its therapeutic effect. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Additive Effect 
• An additive effect occurs when two or more “like” drugs 
are combined. 
– Example: Codeine with acetaminophen work together 
to produce better pain control. 
• An additive effect may be intentional or may 
unintentionally cause harm. 
– Example: Alcohol and aspirin can both cause GI 
bleeding; taken together they greatly increase the 
risk. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Synergistic Effect 
• A synergistic effect occurs when two or more “unlike” 
drugs are used together to produce a combined effect. 
• Consider the following example: 
– A beneficial synergistic effect occurs when two 
different types of antibiotics that work in very 
different ways are combined, such as penicillin G and 
an aminoglycoside antibiotic. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Potentiated Effect 
• Potentiation is an interaction in which the effect of only 
one of the two drugs is increased. 
• In other words, a drug that has a mild effect enhances 
the effect of a second drug. 
– Example: Hydroxyzine increases the effect of 
morphine. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Antagonistic Effect 
• An antagonistic drug interaction is the opposite of a 
synergistic effect. 
• It results in a therapeutic effect that is less than the 
effect of either drug alone because the second drug 
either diminishes or cancels the effects of the first drug. 
• Antagonistic interactions can also occur at receptor sites. 
– Example: Protamine reverses the action of heparin. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins 
Question 
• When naloxone is given with morphine, it causes what 
type of drug reaction? 
– A. Additive effect 
– B. Synergistic effect 
– C. Potentiated effect 
– D. Antagonistic effect
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins 
Answer 
• D. Antagonistic effect 
• Rationale: Antagonistic interactions can also occur at 
receptor sites. Naloxone is a narcotic antagonist used 
to correct narcotic overdosage by displacing the 
morphine molecule off the receptor site.
Drug Incompatibilities 
• Chemical incompatibilities 
– Chemical incompatibilities between drugs change 
both the drug’s structure and its pharmacologic 
properties. 
• Physical incompatibilities 
– Physical incompatibilities occur when two drugs are 
mixed together. 
– The mixture results in the formation of a precipitate. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Assessment of Core Patient Variables 
• Health status 
– Concurrent medical conditions may increase the risk 
of adverse effects from drug therapy. 
– A patient’s chronic health condition may also 
necessitate drug therapy that may interact with other 
drugs. 
• Life span and gender 
– A patient’s age can greatly increase the risk of 
adverse effects from drug therapy. 
– In addition, older adults are more likely to be 
receiving polypharmacy for multiple chronic illnesses. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Assessment of Core Patient Variables 
(cont.) 
• Lifestyle, diet, and habits 
– The patient’s lifestyle, diet, and other health habits 
can have an impact on drug interactions. 
• Environment 
– The patient’s environment may increase the 
likelihood that a certain adverse effect will occur. 
– For instance, some antibiotics can cause the adverse 
effect of photosensitivity. 
– The environment in which drug therapy is 
administered can also play a role in the early 
detection of adverse effects. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Assessment of Core Patient Variables 
(cont.) 
• Culture and inherited traits 
– Researchers are beginning to study responses to 
drug therapy that are genetically determined in 
various ethnic and racial populations. 
– These responses may place the patient at greater 
risk than the rest of the global population for adverse 
effects or drug interactions. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Nursing Diagnoses and Outcomes 
• Risk for Infection related to drug-induced myelosuppression 
– Desired outcome: The patient will not develop infection 
while on drug therapy. 
• Imbalanced nutrition: Less Than Body Requirements related to 
drug-induced nausea, vomiting, anorexia, stomatitis 
– Desired outcome: Despite adverse effects, the patient 
will receive enough nourishment to meet physiologic 
needs. 
• Risk for Poisoning (Toxicity) related to use of drug with a 
narrow therapeutic index 
– Desired outcome: The patient will receive drug therapy 
without harmful or poisonous effects. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Planning and Intervention 
• Maximizing therapeutic effects 
– When drug interactions are intentional and desirable, 
it is important to give the drugs at the prescribed 
time intervals. 
• Minimizing adverse effects 
– To help protect the patient from serious adverse 
effects and drug interactions, obtain a drug history 
from the patient. 
– If a patient is taking a drug that may interact with 
another drug, the drugs should not be 
coadministered. 
– Throughout therapy, monitor the patient for signs 
and symptoms of interactions and adverse effects. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Providing Patient and Family Education 
• Inform the patient and family about adverse effects and 
drug interactions. 
• Initial instruction includes teaching the patient how to 
minimize the occurrence of these effects. 
• Teach the patient which effects to expect, which to report 
to the prescriber, and which require immediate medical 
attention. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Assessment and Evaluation 
• During drug therapy, monitor for adverse effects and 
drug interactions. 
• Consider the possibility of a drug interaction each time a 
new drug is added to the treatment plan. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

More Related Content

What's hot

Introduction to pharmacology for PCL Nursing
Introduction to pharmacology for PCL NursingIntroduction to pharmacology for PCL Nursing
Introduction to pharmacology for PCL Nursingsarosem
 
Drug interactions
Drug interactionsDrug interactions
Drug interactionsvelspharmd
 
Drug development process
Drug development process Drug development process
Drug development process Zobayer Hossain
 
Pharmacology: Class Session 1 and 2 Introduction to Pharmacology
Pharmacology: Class Session 1 and 2 Introduction to PharmacologyPharmacology: Class Session 1 and 2 Introduction to Pharmacology
Pharmacology: Class Session 1 and 2 Introduction to PharmacologyMariaJose2001
 
Pharmacotherapeutics
PharmacotherapeuticsPharmacotherapeutics
Pharmacotherapeuticsatharshamim
 
Essential medicine list
Essential medicine listEssential medicine list
Essential medicine listmigom doley
 
3. pharma medication orders
3. pharma medication orders3. pharma medication orders
3. pharma medication ordersjhonee balmeo
 
Sources of drug information
Sources of drug informationSources of drug information
Sources of drug informationSumit Kumar
 
Ppt chapter 04
Ppt chapter 04Ppt chapter 04
Ppt chapter 04stanbridge
 
02 Pharmacologic Principles Upd
02 Pharmacologic Principles Upd02 Pharmacologic Principles Upd
02 Pharmacologic Principles UpdNurse Uragon
 
Risk benefit assessment
Risk benefit assessmentRisk benefit assessment
Risk benefit assessmentDRMOHITKHER
 
Preclinical studies
Preclinical studiesPreclinical studies
Preclinical studiesAzeemsales
 
Industrial pharmacy
Industrial pharmacyIndustrial pharmacy
Industrial pharmacyWilliam Dube
 
Rational use of medicine
Rational use of medicineRational use of medicine
Rational use of medicineMuhammad Arsal
 
Incompatibilities of drug admixtures
Incompatibilities of drug admixtures Incompatibilities of drug admixtures
Incompatibilities of drug admixtures Ali Al Samawy
 
Role of pharmacists in combating drug resistatnce by neel ratnam.
Role of pharmacists in combating drug resistatnce by neel ratnam.Role of pharmacists in combating drug resistatnce by neel ratnam.
Role of pharmacists in combating drug resistatnce by neel ratnam.neel ratnam
 
Community pharmacy
Community pharmacyCommunity pharmacy
Community pharmacyKARTHIKA K.J
 

What's hot (20)

Introduction to pharmacology for PCL Nursing
Introduction to pharmacology for PCL NursingIntroduction to pharmacology for PCL Nursing
Introduction to pharmacology for PCL Nursing
 
Drug interactions
Drug interactionsDrug interactions
Drug interactions
 
Drug development process
Drug development process Drug development process
Drug development process
 
Prescription ppt
Prescription pptPrescription ppt
Prescription ppt
 
Pharmacology: Class Session 1 and 2 Introduction to Pharmacology
Pharmacology: Class Session 1 and 2 Introduction to PharmacologyPharmacology: Class Session 1 and 2 Introduction to Pharmacology
Pharmacology: Class Session 1 and 2 Introduction to Pharmacology
 
Pharmacotherapeutics
PharmacotherapeuticsPharmacotherapeutics
Pharmacotherapeutics
 
Essential medicine list
Essential medicine listEssential medicine list
Essential medicine list
 
3. pharma medication orders
3. pharma medication orders3. pharma medication orders
3. pharma medication orders
 
Sources of drug information
Sources of drug informationSources of drug information
Sources of drug information
 
Ppt chapter 04
Ppt chapter 04Ppt chapter 04
Ppt chapter 04
 
New Drug Development Process
New Drug Development ProcessNew Drug Development Process
New Drug Development Process
 
02 Pharmacologic Principles Upd
02 Pharmacologic Principles Upd02 Pharmacologic Principles Upd
02 Pharmacologic Principles Upd
 
Risk benefit assessment
Risk benefit assessmentRisk benefit assessment
Risk benefit assessment
 
Preclinical studies
Preclinical studiesPreclinical studies
Preclinical studies
 
Pharmacoepidemiology
PharmacoepidemiologyPharmacoepidemiology
Pharmacoepidemiology
 
Industrial pharmacy
Industrial pharmacyIndustrial pharmacy
Industrial pharmacy
 
Rational use of medicine
Rational use of medicineRational use of medicine
Rational use of medicine
 
Incompatibilities of drug admixtures
Incompatibilities of drug admixtures Incompatibilities of drug admixtures
Incompatibilities of drug admixtures
 
Role of pharmacists in combating drug resistatnce by neel ratnam.
Role of pharmacists in combating drug resistatnce by neel ratnam.Role of pharmacists in combating drug resistatnce by neel ratnam.
Role of pharmacists in combating drug resistatnce by neel ratnam.
 
Community pharmacy
Community pharmacyCommunity pharmacy
Community pharmacy
 

Viewers also liked

Combined effects of Drugs, Pharmacology
Combined effects of Drugs, PharmacologyCombined effects of Drugs, Pharmacology
Combined effects of Drugs, PharmacologyDhruva Sharma
 
Drug interactions their types, examples and role
Drug interactions their types, examples and roleDrug interactions their types, examples and role
Drug interactions their types, examples and roleYousra Ashraf
 
Final seminar 1 oct 13
Final seminar  1 oct 13Final seminar  1 oct 13
Final seminar 1 oct 13Pooja Goswami
 
Adams ch05 lecture
Adams ch05 lectureAdams ch05 lecture
Adams ch05 lectureTheSlaps
 
Estimating the Maximum Safe Starting Dose for First-in-Human Clinical Trials
Estimating the Maximum Safe Starting Dose for First-in-Human Clinical TrialsEstimating the Maximum Safe Starting Dose for First-in-Human Clinical Trials
Estimating the Maximum Safe Starting Dose for First-in-Human Clinical TrialsMaRS Discovery District
 
Antibiotics lecture may 2010
Antibiotics lecture may 2010Antibiotics lecture may 2010
Antibiotics lecture may 2010Bruno Mmassy
 
Antibiotic classification
Antibiotic classificationAntibiotic classification
Antibiotic classificationAparna Rajeevi
 
Adams ch01 lecture
Adams ch01 lectureAdams ch01 lecture
Adams ch01 lectureTheSlaps
 
Adams ch04 lecture
Adams ch04 lectureAdams ch04 lecture
Adams ch04 lectureTheSlaps
 
Pharmacokinetics
PharmacokineticsPharmacokinetics
PharmacokineticsRajan Kumar
 
Chapter 5 How and Why Drugs Work
Chapter 5 How and Why Drugs WorkChapter 5 How and Why Drugs Work
Chapter 5 How and Why Drugs WorkMichelle Meyer
 
Pharmacodynamics
PharmacodynamicsPharmacodynamics
PharmacodynamicsKhalid
 
Basic principles in pharmacology pharmacokinetics - pharmacology
Basic principles in pharmacology pharmacokinetics - pharmacology Basic principles in pharmacology pharmacokinetics - pharmacology
Basic principles in pharmacology pharmacokinetics - pharmacology Areej Abu Hanieh
 
Drug interaction final edition -- animated
Drug interaction   final edition -- animatedDrug interaction   final edition -- animated
Drug interaction final edition -- animatedAhmed Omar
 
Ch02 Drug Receptor Interactions And Pharmacodynamics
Ch02 Drug Receptor Interactions And PharmacodynamicsCh02 Drug Receptor Interactions And Pharmacodynamics
Ch02 Drug Receptor Interactions And Pharmacodynamicsaxix
 

Viewers also liked (20)

Combined effects of Drugs, Pharmacology
Combined effects of Drugs, PharmacologyCombined effects of Drugs, Pharmacology
Combined effects of Drugs, Pharmacology
 
Drug interactions their types, examples and role
Drug interactions their types, examples and roleDrug interactions their types, examples and role
Drug interactions their types, examples and role
 
Final seminar 1 oct 13
Final seminar  1 oct 13Final seminar  1 oct 13
Final seminar 1 oct 13
 
Drug interactions
Drug interactionsDrug interactions
Drug interactions
 
drug interactions
drug interactionsdrug interactions
drug interactions
 
DRUG INTERACTION
DRUG INTERACTIONDRUG INTERACTION
DRUG INTERACTION
 
Adams ch05 lecture
Adams ch05 lectureAdams ch05 lecture
Adams ch05 lecture
 
Estimating the Maximum Safe Starting Dose for First-in-Human Clinical Trials
Estimating the Maximum Safe Starting Dose for First-in-Human Clinical TrialsEstimating the Maximum Safe Starting Dose for First-in-Human Clinical Trials
Estimating the Maximum Safe Starting Dose for First-in-Human Clinical Trials
 
Antibiotics lecture may 2010
Antibiotics lecture may 2010Antibiotics lecture may 2010
Antibiotics lecture may 2010
 
Antibiotic classification
Antibiotic classificationAntibiotic classification
Antibiotic classification
 
Adams ch01 lecture
Adams ch01 lectureAdams ch01 lecture
Adams ch01 lecture
 
Adams ch04 lecture
Adams ch04 lectureAdams ch04 lecture
Adams ch04 lecture
 
Drug interactions
Drug interactionsDrug interactions
Drug interactions
 
Pharmacokinetics
PharmacokineticsPharmacokinetics
Pharmacokinetics
 
Chapter 5 How and Why Drugs Work
Chapter 5 How and Why Drugs WorkChapter 5 How and Why Drugs Work
Chapter 5 How and Why Drugs Work
 
Pharmacodynamics
PharmacodynamicsPharmacodynamics
Pharmacodynamics
 
Drug interactions
Drug interactionsDrug interactions
Drug interactions
 
Basic principles in pharmacology pharmacokinetics - pharmacology
Basic principles in pharmacology pharmacokinetics - pharmacology Basic principles in pharmacology pharmacokinetics - pharmacology
Basic principles in pharmacology pharmacokinetics - pharmacology
 
Drug interaction final edition -- animated
Drug interaction   final edition -- animatedDrug interaction   final edition -- animated
Drug interaction final edition -- animated
 
Ch02 Drug Receptor Interactions And Pharmacodynamics
Ch02 Drug Receptor Interactions And PharmacodynamicsCh02 Drug Receptor Interactions And Pharmacodynamics
Ch02 Drug Receptor Interactions And Pharmacodynamics
 

Similar to Ppt chapter 05

Ppt chapter 08-1
Ppt chapter 08-1Ppt chapter 08-1
Ppt chapter 08-1stanbridge
 
Ppt chapter 18
Ppt chapter 18Ppt chapter 18
Ppt chapter 18stanbridge
 
Ppt chapter 22
Ppt chapter 22Ppt chapter 22
Ppt chapter 22stanbridge
 
Ppt chapter 09-1
Ppt chapter 09-1Ppt chapter 09-1
Ppt chapter 09-1stanbridge
 
Ppt chapter 07-1
Ppt chapter 07-1Ppt chapter 07-1
Ppt chapter 07-1stanbridge
 
Ppt chapter 01
Ppt chapter 01Ppt chapter 01
Ppt chapter 01stanbridge
 
Ppt chapter 41
Ppt chapter 41Ppt chapter 41
Ppt chapter 41stanbridge
 
Ppt chapter 41
Ppt chapter 41Ppt chapter 41
Ppt chapter 41stanbridge
 
Ppt chapter 01-1
Ppt chapter 01-1Ppt chapter 01-1
Ppt chapter 01-1stanbridge
 
Ppt chapter 53-1
Ppt chapter 53-1Ppt chapter 53-1
Ppt chapter 53-1stanbridge
 
Ppt chapter 11-1
Ppt chapter 11-1Ppt chapter 11-1
Ppt chapter 11-1stanbridge
 
Ppt chapter 16
Ppt chapter 16Ppt chapter 16
Ppt chapter 16stanbridge
 
Ppt chapter 20
Ppt chapter 20Ppt chapter 20
Ppt chapter 20stanbridge
 
Ppt chapter 20
Ppt chapter 20Ppt chapter 20
Ppt chapter 20stanbridge
 
Ppt chapter 50
Ppt chapter 50Ppt chapter 50
Ppt chapter 50stanbridge
 
Ppt chapter 32
Ppt chapter 32Ppt chapter 32
Ppt chapter 32stanbridge
 
Ppt chapter 40
Ppt chapter 40Ppt chapter 40
Ppt chapter 40stanbridge
 
Ppt chapter 52
Ppt chapter 52Ppt chapter 52
Ppt chapter 52stanbridge
 
Adverse Drug Reaction
Adverse Drug ReactionAdverse Drug Reaction
Adverse Drug ReactionSabaShaikh76
 

Similar to Ppt chapter 05 (20)

Ppt chapter 08-1
Ppt chapter 08-1Ppt chapter 08-1
Ppt chapter 08-1
 
Ppt chapter 18
Ppt chapter 18Ppt chapter 18
Ppt chapter 18
 
Ppt chapter 22
Ppt chapter 22Ppt chapter 22
Ppt chapter 22
 
Ppt chapter 09-1
Ppt chapter 09-1Ppt chapter 09-1
Ppt chapter 09-1
 
Ppt chapter 07-1
Ppt chapter 07-1Ppt chapter 07-1
Ppt chapter 07-1
 
Ppt chapter 01
Ppt chapter 01Ppt chapter 01
Ppt chapter 01
 
Ppt chapter 41
Ppt chapter 41Ppt chapter 41
Ppt chapter 41
 
Ppt chapter 41
Ppt chapter 41Ppt chapter 41
Ppt chapter 41
 
Ppt chapter 01-1
Ppt chapter 01-1Ppt chapter 01-1
Ppt chapter 01-1
 
Ppt chapter 53-1
Ppt chapter 53-1Ppt chapter 53-1
Ppt chapter 53-1
 
Ppt chapter 11-1
Ppt chapter 11-1Ppt chapter 11-1
Ppt chapter 11-1
 
Ppt chapter 16
Ppt chapter 16Ppt chapter 16
Ppt chapter 16
 
Ppt chapter 20
Ppt chapter 20Ppt chapter 20
Ppt chapter 20
 
Ppt chapter 20
Ppt chapter 20Ppt chapter 20
Ppt chapter 20
 
Ppt chapter 50
Ppt chapter 50Ppt chapter 50
Ppt chapter 50
 
Ppt chapter 32
Ppt chapter 32Ppt chapter 32
Ppt chapter 32
 
Ppt chapter 40
Ppt chapter 40Ppt chapter 40
Ppt chapter 40
 
Dose response relationship
Dose response relationshipDose response relationship
Dose response relationship
 
Ppt chapter 52
Ppt chapter 52Ppt chapter 52
Ppt chapter 52
 
Adverse Drug Reaction
Adverse Drug ReactionAdverse Drug Reaction
Adverse Drug Reaction
 

More from stanbridge

Micro Lab 3 Lecture
Micro Lab 3 LectureMicro Lab 3 Lecture
Micro Lab 3 Lecturestanbridge
 
Creating a poster v2
Creating a poster v2Creating a poster v2
Creating a poster v2stanbridge
 
Creating a poster
Creating a posterCreating a poster
Creating a posterstanbridge
 
OT 5018 Thesis Dissemination
OT 5018 Thesis DisseminationOT 5018 Thesis Dissemination
OT 5018 Thesis Disseminationstanbridge
 
Ot5101 005 week 5
Ot5101 005 week 5Ot5101 005 week 5
Ot5101 005 week 5stanbridge
 
Ot5101 005 week4
Ot5101 005 week4Ot5101 005 week4
Ot5101 005 week4stanbridge
 
Compliance, motivation, and health behaviors
Compliance, motivation, and health behaviors Compliance, motivation, and health behaviors
Compliance, motivation, and health behaviors stanbridge
 
Ch 5 developmental stages of the learner
Ch 5   developmental stages of the learnerCh 5   developmental stages of the learner
Ch 5 developmental stages of the learnerstanbridge
 
OT 5101 week2 theory policy
OT 5101 week2 theory policyOT 5101 week2 theory policy
OT 5101 week2 theory policystanbridge
 
OT 5101 week3 planning needs assessment
OT 5101 week3 planning needs assessmentOT 5101 week3 planning needs assessment
OT 5101 week3 planning needs assessmentstanbridge
 
NUR 304 Chapter005
NUR 304 Chapter005NUR 304 Chapter005
NUR 304 Chapter005stanbridge
 
NUR 3043 Chapter007
NUR 3043 Chapter007NUR 3043 Chapter007
NUR 3043 Chapter007stanbridge
 
NUR 3043 Chapter006
NUR 3043 Chapter006NUR 3043 Chapter006
NUR 3043 Chapter006stanbridge
 
NUR 3043 Chapter004
NUR 3043 Chapter004NUR 3043 Chapter004
NUR 3043 Chapter004stanbridge
 
3043 Chapter009
3043 Chapter0093043 Chapter009
3043 Chapter009stanbridge
 
3043 Chapter008
 3043 Chapter008 3043 Chapter008
3043 Chapter008stanbridge
 
Melnyk ppt chapter_21
Melnyk ppt chapter_21Melnyk ppt chapter_21
Melnyk ppt chapter_21stanbridge
 
Melnyk ppt chapter_22
Melnyk ppt chapter_22Melnyk ppt chapter_22
Melnyk ppt chapter_22stanbridge
 

More from stanbridge (20)

Micro Lab 3 Lecture
Micro Lab 3 LectureMicro Lab 3 Lecture
Micro Lab 3 Lecture
 
Creating a poster v2
Creating a poster v2Creating a poster v2
Creating a poster v2
 
Creating a poster
Creating a posterCreating a poster
Creating a poster
 
Sample poster
Sample posterSample poster
Sample poster
 
OT 5018 Thesis Dissemination
OT 5018 Thesis DisseminationOT 5018 Thesis Dissemination
OT 5018 Thesis Dissemination
 
Ot5101 005 week 5
Ot5101 005 week 5Ot5101 005 week 5
Ot5101 005 week 5
 
Ot5101 005 week4
Ot5101 005 week4Ot5101 005 week4
Ot5101 005 week4
 
Compliance, motivation, and health behaviors
Compliance, motivation, and health behaviors Compliance, motivation, and health behaviors
Compliance, motivation, and health behaviors
 
Ch 5 developmental stages of the learner
Ch 5   developmental stages of the learnerCh 5   developmental stages of the learner
Ch 5 developmental stages of the learner
 
OT 5101 week2 theory policy
OT 5101 week2 theory policyOT 5101 week2 theory policy
OT 5101 week2 theory policy
 
OT 5101 week3 planning needs assessment
OT 5101 week3 planning needs assessmentOT 5101 week3 planning needs assessment
OT 5101 week3 planning needs assessment
 
Ot5101 week1
Ot5101 week1Ot5101 week1
Ot5101 week1
 
NUR 304 Chapter005
NUR 304 Chapter005NUR 304 Chapter005
NUR 304 Chapter005
 
NUR 3043 Chapter007
NUR 3043 Chapter007NUR 3043 Chapter007
NUR 3043 Chapter007
 
NUR 3043 Chapter006
NUR 3043 Chapter006NUR 3043 Chapter006
NUR 3043 Chapter006
 
NUR 3043 Chapter004
NUR 3043 Chapter004NUR 3043 Chapter004
NUR 3043 Chapter004
 
3043 Chapter009
3043 Chapter0093043 Chapter009
3043 Chapter009
 
3043 Chapter008
 3043 Chapter008 3043 Chapter008
3043 Chapter008
 
Melnyk ppt chapter_21
Melnyk ppt chapter_21Melnyk ppt chapter_21
Melnyk ppt chapter_21
 
Melnyk ppt chapter_22
Melnyk ppt chapter_22Melnyk ppt chapter_22
Melnyk ppt chapter_22
 

Ppt chapter 05

  • 1. Chapter 5 Adverse Effects and Drug Interactions Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 2. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Question • All drugs have some type of adverse effect(s). – A. True – B. False
  • 3. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Answer • A. True • Rationale: All drugs produce some type of adverse effect; some of the effects are mild, and others can be life threatening.
  • 4. Adverse Effects • An adverse effect of drug therapy is a usually undesirable effect other than the intended therapeutic effect. • It may occur even with normal drug dosing. • An adverse effect may result from – Too much of a therapeutic effect – Other pharmacodynamic effects of the drug Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 5. Drug Interactions • A drug interaction occurs when two drugs or a drug and another element have an effect on each other. • This interaction may – Increase or decrease the therapeutic effect of the Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins drugs – Create a new effect – Increase the incidence of an adverse effect
  • 6. Adverse Effects • Every drug can produce adverse effects. • Serious adverse effects lead to the withdrawal of a small number of drugs from the market every year. • It is important for nurses and other health care professionals to be alert for adverse effects from drug therapy. • Serious adverse reactions to a drug, especially a newly approved drug, should be reported to a national database. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 7. Allergic and Idiosyncratic Response • An allergic response is an immune system response. • The antigen–antibody response when the drug is taken again • Symptoms may become more severe each time the drug is introduced into the body. • The most serious allergic response is called anaphylaxis. • Idiosyncratic responses are unusual and in fact may be the opposite of what is anticipated. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 8. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Question • Which of the following is not a symptom of anaphylaxis? – A. Bronchospasms – B. Vasodilation – C. Convulsions – D. Pruritus
  • 9. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Answer • D. Pruritus • Rationale: Pruritus is itching and is not a sign of anaphylaxis but is considered an allergic reaction.
  • 10. Toxicities • Neurotoxicity (central nervous system) – Signs and symptoms: drowsiness, auditory and visual disturbances, and seizures • Hepatotoxicity (liver) – Manifestations include hepatitis, jaundice, elevated liver enzyme levels, and fatty infiltration of the liver. • Nephrotoxicity (kidneys) – Signs and symptoms: decreased urinary output, elevated blood urea nitrogen, increased serum creatinine, altered acid-base balance, and electrolyte imbalances Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 11. Toxicities (cont.) • Ototoxicity (eighth cranial nerve) – Signs and symptoms: tinnitus, hearing loss, light-headedness, vertigo, nausea, and vomiting • Cardiotoxicity (heart) – Signs and symptoms: irregularities in conduction, heart failure, and damage to the myocardium • Immunotoxicity (immune system) – Signs and symptoms: immunosuppression, increased incidence of bacterial, viral, and parasitic infections Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 12. Drug Interactions • Drug interactions occur when one drug is affected in some way by another drug. • Drug interactions may be beneficial. • Negative effects from drug interactions are those that decrease the therapeutic effect. • Drug interactions may take place in any phase of pharmacokinetics. • Drug interactions can also change the pharmacodynamics of a drug. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 13. Drug Interactions (cont.) Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 14. Drug Interactions Affecting Absorption • Drug absorption is often decreased because of drug interactions. • If a drug binds with another substance in the GI tract, less of the drug is available to be absorbed. • This binding of a drug is termed chelation. • Drug absorption may also be increased as a result of a drug interaction or the presence of food in the GI tract. • The exact extent of changes in drug absorption caused by drug interactions is often difficult to predict. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 15. Drug Interactions Affecting Distribution • Distribution is affected by two types of drug interactions. • The first is competitive protein binding. • The second is drug alteration of the extracellular pH. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 16. Drug Interactions Affecting Metabolism • Probably the most important and common drug interaction is one that alters the metabolism of a drug. • Drugs that induce a hepatic enzyme increase the amount of that enzyme in the liver. • If two drugs that affect the cytochrome P-450 system must be administered to a patient together, the dose of one of the drugs may have to be adjusted. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 17. Drug Interactions Affecting Excretion • Drugs can alter renal filtration, renal reabsorption, or renal secretion. • Glomerular filtration is dependent on blood flow to the kidney. • Drugs that decrease cardiac output decrease the amount of circulating blood that is sent to the kidneys. • Renal reabsorption of a drug is dependent on whether a drug is ionized. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 18. Drug Interactions Affecting Pharmacodynamics • Drug interactions may affect the pharmacodynamics of one or both drugs administered. • The overall effect may be positive or negative. • The drug that has the weaker affinity for the receptor will not be able to exert its therapeutic effect. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 19. Additive Effect • An additive effect occurs when two or more “like” drugs are combined. – Example: Codeine with acetaminophen work together to produce better pain control. • An additive effect may be intentional or may unintentionally cause harm. – Example: Alcohol and aspirin can both cause GI bleeding; taken together they greatly increase the risk. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 20. Synergistic Effect • A synergistic effect occurs when two or more “unlike” drugs are used together to produce a combined effect. • Consider the following example: – A beneficial synergistic effect occurs when two different types of antibiotics that work in very different ways are combined, such as penicillin G and an aminoglycoside antibiotic. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 21. Potentiated Effect • Potentiation is an interaction in which the effect of only one of the two drugs is increased. • In other words, a drug that has a mild effect enhances the effect of a second drug. – Example: Hydroxyzine increases the effect of morphine. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 22. Antagonistic Effect • An antagonistic drug interaction is the opposite of a synergistic effect. • It results in a therapeutic effect that is less than the effect of either drug alone because the second drug either diminishes or cancels the effects of the first drug. • Antagonistic interactions can also occur at receptor sites. – Example: Protamine reverses the action of heparin. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 23. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Question • When naloxone is given with morphine, it causes what type of drug reaction? – A. Additive effect – B. Synergistic effect – C. Potentiated effect – D. Antagonistic effect
  • 24. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Answer • D. Antagonistic effect • Rationale: Antagonistic interactions can also occur at receptor sites. Naloxone is a narcotic antagonist used to correct narcotic overdosage by displacing the morphine molecule off the receptor site.
  • 25. Drug Incompatibilities • Chemical incompatibilities – Chemical incompatibilities between drugs change both the drug’s structure and its pharmacologic properties. • Physical incompatibilities – Physical incompatibilities occur when two drugs are mixed together. – The mixture results in the formation of a precipitate. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 26. Assessment of Core Patient Variables • Health status – Concurrent medical conditions may increase the risk of adverse effects from drug therapy. – A patient’s chronic health condition may also necessitate drug therapy that may interact with other drugs. • Life span and gender – A patient’s age can greatly increase the risk of adverse effects from drug therapy. – In addition, older adults are more likely to be receiving polypharmacy for multiple chronic illnesses. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 27. Assessment of Core Patient Variables (cont.) • Lifestyle, diet, and habits – The patient’s lifestyle, diet, and other health habits can have an impact on drug interactions. • Environment – The patient’s environment may increase the likelihood that a certain adverse effect will occur. – For instance, some antibiotics can cause the adverse effect of photosensitivity. – The environment in which drug therapy is administered can also play a role in the early detection of adverse effects. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 28. Assessment of Core Patient Variables (cont.) • Culture and inherited traits – Researchers are beginning to study responses to drug therapy that are genetically determined in various ethnic and racial populations. – These responses may place the patient at greater risk than the rest of the global population for adverse effects or drug interactions. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 29. Nursing Diagnoses and Outcomes • Risk for Infection related to drug-induced myelosuppression – Desired outcome: The patient will not develop infection while on drug therapy. • Imbalanced nutrition: Less Than Body Requirements related to drug-induced nausea, vomiting, anorexia, stomatitis – Desired outcome: Despite adverse effects, the patient will receive enough nourishment to meet physiologic needs. • Risk for Poisoning (Toxicity) related to use of drug with a narrow therapeutic index – Desired outcome: The patient will receive drug therapy without harmful or poisonous effects. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 30. Planning and Intervention • Maximizing therapeutic effects – When drug interactions are intentional and desirable, it is important to give the drugs at the prescribed time intervals. • Minimizing adverse effects – To help protect the patient from serious adverse effects and drug interactions, obtain a drug history from the patient. – If a patient is taking a drug that may interact with another drug, the drugs should not be coadministered. – Throughout therapy, monitor the patient for signs and symptoms of interactions and adverse effects. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 31. Providing Patient and Family Education • Inform the patient and family about adverse effects and drug interactions. • Initial instruction includes teaching the patient how to minimize the occurrence of these effects. • Teach the patient which effects to expect, which to report to the prescriber, and which require immediate medical attention. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 32. Assessment and Evaluation • During drug therapy, monitor for adverse effects and drug interactions. • Consider the possibility of a drug interaction each time a new drug is added to the treatment plan. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins